NASDAQ:ELGX - Endologix Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$5.30 -0.04 (-0.75 %)
(As of 07/23/2018 06:00 AM ET)
Previous Close$5.30
Today's Range$5.04 - $5.37
52-Week Range$3.75 - $6.72
Volume333,130 shs
Average Volume294,292 shs
Market Capitalization$445.26 million
P/E RatioN/A
Dividend YieldN/A
Beta0.44
Endologix logoEndologix, Inc. develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States and internationally. It offers minimally-invasive endovascular repair (EVAR) products, including AFX (Anatomical Fixation) endovascular AAA system, which is a minimally invasive delivery system; VELA Proximal Endograft, which is designed for the treatment of proximal aortic neck anatomies with AFX; and the ovation abdominal stent graft system. The company also provides endovascular sealing (EVAS) product that is based on the Nellix EVAS system to seal the aneurysm, and provides blood flow to the legs through two blood lumens. In addition, it offers proximal aortic extensions and limb extensions which allows physicians to customize the implant to fit the patient's anatomy; and accessories to facilitate the delivery of its EVAR and EVAS products, including compatible guidewires, inflation devices, and snares. The company offers its EVAR products under Ovation, Powerlink System, IntuiTrak, AFX, VELA Proximal Endograft brand names; and EVAS products under the Nellix EVAS system brand name. It sells its products through direct sales force, network of agents, and independent distributors or agents. The company was formerly known as Radiance Medical Systems, Inc. and changed its name to Endologix, Inc. in May 2002. Endologix, Inc. was founded in 1992 and is headquartered in Irvine, California.

Receive ELGX News and Ratings via Email

Sign-up to receive the latest news and ratings for ELGX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Surgical & medical instruments
Sub-IndustryHealth Care Supplies
SectorMedical
SymbolNASDAQ:ELGX
CUSIP29266S10
Phone949-595-7200

Debt

Debt-to-Equity Ratio3.58
Current Ratio2.13
Quick Ratio1.37

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$181.16 million
Price / Sales2.46
Cash FlowN/A
Price / CashN/A
Book Value$0.90 per share
Price / Book5.89

Profitability

EPS (Most Recent Fiscal Year)($0.48)
Net Income$-66,400,000.00
Net Margins-35.86%
Return on Equity-47.01%
Return on Assets-9.92%

Miscellaneous

Employees675
Outstanding Shares84,010,000
Market Cap$445.26

Endologix (NASDAQ:ELGX) Frequently Asked Questions

What is Endologix's stock symbol?

Endologix trades on the NASDAQ under the ticker symbol "ELGX."

How were Endologix's earnings last quarter?

Endologix, Inc. (NASDAQ:ELGX) released its earnings results on Wednesday, May, 2nd. The medical instruments supplier reported ($0.15) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.18) by $0.03. The medical instruments supplier had revenue of $42.28 million for the quarter, compared to analyst estimates of $41.14 million. Endologix had a negative return on equity of 47.01% and a negative net margin of 35.86%. Endologix's revenue was down .8% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.18) earnings per share. View Endologix's Earnings History.

When is Endologix's next earnings date?

Endologix is scheduled to release their next quarterly earnings announcement on Thursday, August, 9th 2018. View Earnings Estimates for Endologix.

What price target have analysts set for ELGX?

6 analysts have issued 1-year price targets for Endologix's shares. Their predictions range from $4.00 to $5.00. On average, they anticipate Endologix's stock price to reach $4.75 in the next twelve months. This suggests that the stock has a possible downside of 10.4%. View Analyst Ratings for Endologix.

What is the consensus analysts' recommendation for Endologix?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Endologix in the last year. There are currently 1 sell rating, 4 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold."

What are Wall Street analysts saying about Endologix stock?

Here are some recent quotes from research analysts about Endologix stock:
  • 1. According to Zacks Investment Research, "Endologix, Inc. develops, manufactures and markets products for the treatment of coronary and vascular diseases. A leader in the emerging field of vascular brachytherapy, Endologix, has developed a unique method for the delivery of radiation to prevent restenosis following the interventional treatment of atherosclerosis. " (5/7/2018)
  • 2. Canaccord Genuity analysts commented, "Alimera reported 2Q17 Iluvien US sales of $8.1M which was above our estimate of." (8/4/2017)

Are investors shorting Endologix?

Endologix saw a decline in short interest in the month of June. As of June 15th, there was short interest totalling 6,243,271 shares, a decline of 15.7% from the May 31st total of 7,409,544 shares. Based on an average daily trading volume, of 639,950 shares, the short-interest ratio is presently 9.8 days. Currently, 8.2% of the company's shares are short sold. View Endologix's Current Options Chain.

Who are some of Endologix's key competitors?

Who are Endologix's key executives?

Endologix's management team includes the folowing people:
  • Mr. John Onopchenko, Chief Exec. Officer (Age 59)
  • Mr. Vaseem Mahboob, Chief Financial Officer (Age 49)
  • Dr. Michael V. Chobotov, Chief Technology Officer (Age 57)
  • Mr. Robert D. Mitchell, Consultant (Age 56)
  • Mr. Jeremy B. Hayden, Gen. Counsel (Age 48)

Has Endologix been receiving favorable news coverage?

Headlines about ELGX stock have trended somewhat positive recently, according to Accern Sentiment. Accern rates the sentiment of media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Endologix earned a media sentiment score of 0.23 on Accern's scale. They also gave news headlines about the medical instruments supplier an impact score of 46.33 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.

How do I buy shares of Endologix?

Shares of ELGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Endologix's stock price today?

One share of ELGX stock can currently be purchased for approximately $5.30.

How big of a company is Endologix?

Endologix has a market capitalization of $445.26 million and generates $181.16 million in revenue each year. The medical instruments supplier earns $-66,400,000.00 in net income (profit) each year or ($0.48) on an earnings per share basis. Endologix employs 675 workers across the globe.

How can I contact Endologix?

Endologix's mailing address is 2 MUSICK, IRVINE CA, 92618. The medical instruments supplier can be reached via phone at 949-595-7200 or via email at [email protected]


MarketBeat Community Rating for Endologix (NASDAQ ELGX)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  359 (Vote Outperform)
Underperform Votes:  341 (Vote Underperform)
Total Votes:  700
MarketBeat's community ratings are surveys of what our community members think about Endologix and other stocks. Vote "Outperform" if you believe ELGX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ELGX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.